Idorsia Ltd. announced the appointment of Dr. Amer Joseph as Executive Vice President, Chief Medical Officer (CMO) & Head of Global Clinical Development, effective May 1, 2026. He succeeds Dr. Alberto Gimona, who is retiring. Amer joins Idorsia from Chiesi Group, where he most recently served as Vice President, Head of Global Clinical Development, leading a global organization spanning clinical development, clinical operations, biometrics, real-world evidence, and digital health.
He delivered late-stage development programs in respiratory, neonatology, cardiovascular and rare diseases, launched three products in 2023, and drove multiple FDA and EMA approvals. Previously, Amer spent over nine years at Bayer, holding global leadership roles in cardiology and nephrology. He played a pivotal role in developing the blockbuster cardio-renal franchise finerenone, leading Phase 2 and Phase 3 programs involving 13,000 patients across 48 countries and steering global health authority interactions.
He also gained rare disease experience at GSK, providing clinical leadership for programs in transthyretin amyloidosis. Amer began his career as a clinician in the United Kingdom, working in leading London hospitals including the London Chest Hospital, St Bartholomew?s, and the Royal London Hospital. He has a deep expertise across the heart-kidney-metabolic axis, strong engagement with global and US key opinion leaders, and considerable experience collaborating with commercial and medical affairs to shape differentiated clinical strategies.
He has authored over 40 peer-reviewed publications in top-tier journals such as NEJM, JAMA, Circulation, European Heart Journal, and JACC, and has contributed to numerous due diligences and business development processes across rare disease, cardiovascular and renal assets.
